Seminars in Oncology

Papers
(The median citation count of Seminars in Oncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
KRAS mutation in pancreatic cancer141
Axillary surgery in breast cancer: An updated historical perspective64
Implications of reactive oxygen species on cancer formation and its treatment47
Chemotherapy-induced peripheral neuropathy and rehabilitation: A review38
Cancer diagnosis in Brazil in the COVID-19 era34
Homologous recombination repair deficiency as a therapeutic target in sarcoma29
Differences in mortality of cancer patients with COVID-19 in a Brazilian cancer center26
COVID-19 vaccine-related axillary lymphadenopathy in breast cancer patients: Case series with a review of literature17
Harnessing natural killer cells for the treatment of multiple myeloma15
Radiation recall dermatitis: A review of the literature14
Novel targeted therapies for advanced non-small lung cancer13
Irreversible electroporation of locally advanced pancreatic cancer13
Liquid Biopsy, the hype vs. hope in molecular and clinical oncology13
The heterogeneity of Epithelioid Hemangioendothelioma (EHE): A case series and review of the literature with emphasis on treatment options13
A review of immune checkpoint blockade in breast cancer12
Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China12
Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management12
Combination therapy in metastatic renal cell carcinoma: Back to the future?12
Future directions in drug development in pancreatic cancer11
Endoscopic ultrasound-guided therapies for pancreatic solid tumors: An overview10
Radiotherapy for locally advanced pancreatic ductal adenocarcinoma10
The psychosocial and emotional experiences of cancer patients during the COVID-19 pandemic: A systematic review9
Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer9
Pancreatic ductal adenocarcinoma in the era of precision medicine9
Management problems in patients with pancreatic cancer from a surgeon's perspective8
Barriers and facilitators to lung cancer screening and follow-up8
PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance8
Non-pharmacologic interventions for improving cancer-related fatigue (CRF): A systematic review of systematic reviews and pooled meta-analysis8
Neoadjuvant chemotherapy for gastric cancer. Has the time to decelerate the enthusiasm passed us by?8
Outcomes with panobinostat in heavily pretreated multiple myeloma patients7
Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain7
Epidemiology and genetics of early onset colorectal cancer—African overview with a focus on Ethiopia7
Pathogenic signaling in multiple myeloma7
Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias7
The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma6
Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies6
Military exposures and lung cancer in United States Veterans6
Comorbidity and life expectancy in shared decision making for lung cancer screening6
Daratumumab: A review of current indications and future directions6
Impact of CT screening in lung cancer: Scientific evidence and literature review6
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review6
IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time6
PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics6
Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far6
Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects5
Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing—The experience of a large oncology center in t5
Examining health related quality of life outcomes in multiple myeloma: Past and future perspectives5
Treatment sequencing of metastatic colorectal cancer based on primary tumor location5
The Impact of HIV on Non-AIDS defining gastrointestinal malignancies: A review5
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans5
Positive attitudes toward clinical trials among military veterans leaves unanswered questions about poor trial accrual5
Is the neutrophil-to-lymphocyte ratio a prognostic factor in non-small cell lung cancer patients who receive adjuvant chemotherapy?5
Gemcitabine plus nab‐paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans4
Complete response in a frail patient with high-grade B-cell lymphoma to only one cycle of R-CHOP or to prolonged COVID-19?4
Landmark trials in the medical oncology management of metastatic breast cancer4
Torticollis as a presenting symptom of pediatric CNS tumors: A systematic review4
A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: The radiation oncologist's perspective4
The knowns and unknowns of disparities, biology, and clinical outcomes in Hispanic and Latinx multiple myeloma patients in the U.S.4
A systematic review with in silico analysis on transcriptomic profile of gallbladder carcinoma4
Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer4
CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety4
“Off-the-shelf” immunotherapies for multiple myeloma4
Global distribution of prophylactic total gastrectomy in E-cadherin (CDH1) mutations4
Immune checkpoint inhibitors in patients with chronic kidney disease: Assessing their ability to cause acute kidney injury and informing their proper use3
COVID 19 pandemic testing time – Crisis or opportunity in disguise for India?3
Modern radiographic imaging in multiple myeloma, what is the minimum requirement?3
Distribution of cancer genes in human chromosomes3
Assessing Outcomes in NSCLC: Radiomic analysis, kinetic analysis and circulating tumor DNA3
The impact of the COVID-19 pandemic on tertiary care cancer center: Analyzing administrative data3
Treatment and outcomes of pediatric patients with cancer and COVID-19 at MAHAK pediatric cancer treatment and research center, Tehran, Iran3
Skin metastases in the clinical and dermoscopic aspects3
Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis3
Preservation of fertility in female: Indications, available options, and current status in Saudi Arabia3
Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study3
Loss of function STK11 alterations and poor outcomes in non–small-cell lung cancer: Literature and case series of US Veterans3
Rare SARS-CoV-2 antibody development in cancer patients3
Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized con3
Lung cancer screening at the VA: Past, present and future3
Current and prospective antibody-based therapies in multiple myeloma3
Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer3
A double-edged sword: Prolonged detection of SARS-COV-2 in patients receiving cancer directed therapy2
Controversies and challenges in lung cancer screening2
Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab2
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis.2
Cancer stage and time from cancer diagnosis to first treatment during the COVID-19 pandemic2
Non-small cell lung cancer in the era of immunotherapy2
Under-representation of women in Randomized Clinical Trials testing anticancer immunotherapy may undermine female patients care. A call to action2
Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review2
PARP inhibitors for prostate cancer2
Exploring the effects of racial and socioeconomic factors on timeliness of lung cancer diagnosis and treatment in Baltimore Veterans2
Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program2
Predictors of treatment refusal in patients with colorectal cancer: A systematic review2
Molecular biomarkers and liquid biopsies in lung cancer2
Lung cancer: Premalignant biology and medical prevention2
Bone-modifying agents for non–small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review1
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment1
Practical guidance for new multiple myeloma treatment regimens: A nursing perspective1
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)1
Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer1
Which future for de-intensified treatments in HPV-related oropharyngeal carcinoma?1
Successful restoration of checkpoint inhibitors efficacy after allogeneic hematopoietic cell transplant for classic Hodgkin lymphoma patients1
Surgery for early-stage lung cancer with video-assisted thoracoscopic surgery versus open thoracotomy: A narrative review1
Overcoming barriers to opioid-induced constipation management in cancer patients1
Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer1
Masthead1
Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions1
Scoping to analyze oncology trial participation in Australia1
Communication strategies during the COVID-19 pandemic: Unforeseen opportunities and drawbacks1
PARP inhibitors in ovarian cancer1
Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701)1
Acute liver failure secondary to malignant infiltration: A single center experience1
Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?1
Masthead1
Inherited predisposition to pancreatic cancer1
Efficacy of memantine in preventing neurocognitive dysfunction induced by radiation therapy in patients with brain metastases: A systematic review of clinical trials1
0.032159805297852